Gary Stetz

Interim Chief Executive Officer at Hepion Pharmaceuticals. Director at Canton Strategic.

Earliest Form D on file: Apr 2026

4 filings at 2 companies

Hepion Pharmaceuticals

Biotech, Red Bank NJ

Interim Chief Executive Officer · signer

Biotech, Red Bank NJ

Canton Strategic

Fintech, Red Bank NJ

Director

Fintech, Red Bank NJ

Signed
Named
Size is amount sold, up to $30M

Filings

4

Aug 5, 2026
Hepion Pharmaceuticals, signed · Form D
$3.055M
of $3.055M
Aug 5, 2026
Hepion Pharmaceuticals
Signed as Interim Chief Executive Officer
$3.055M
$3.055M
Form D
Apr 22, 2026
Hepion Pharmaceuticals, signed · Form D
$700K
of $700K
Apr 22, 2026
Hepion Pharmaceuticals
Signed as Interim Chief Executive Officer
$700K
$700K
Form D
Apr 15, 2026
Canton Strategic, named · Form D
$1.2M
of $1.2M
Apr 15, 2026
Canton Strategic
Named, Director
$1.2M
$1.2M
Form D
Apr 15, 2026
Canton Strategic, named · Form D
$1.74M
of $1.74M
Apr 15, 2026
Canton Strategic
Named, Director
$1.74M
$1.74M
Form D

Network

Also at Canton Strategic and Hepion Pharmaceuticals

2 people

Vincent LoPriore
Director at both, Executive Officer at Hepion Pharmaceuticals
Sireesh Appajosyula
Director at both

Only at Hepion Pharmaceuticals

5 people

Chase LoPriore
Together on 2 filings
Director
Michael Purcell
Together on 2 filings
Director
Dania Fisher
Together on 1 filing
Director
Gary Stetz, II
Together on 1 filing
Director

1 more at Hepion Pharmaceuticals

Only at Canton Strategic

7 people

Mark Wendland
Executive Officer, Director, signed as Chief Executive Officer
Angela Radkowski
Executive Officer
Clay Kahler
Director
Jacob Asbury
Executive Officer

3 more at Canton Strategic